Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus

Abstract

Respiratory syncytial virus (RSV) is a significant viral pathogen that causes respiratory infections in infants, the elderly, and immunocompromised individuals. RSV-related illnesses impose a substantial economic burden worldwide annually. The molecular structure, function, and in vivo interaction mechanisms of RSV have received more comprehensive attention in recent times, and significant progress has been made in developing inhibitors targeting various stages of the RSV replication cycle. These include fusion inhibitors, RSV polymerase inhibitors, and nucleoprotein inhibitors, as well as FDA-approved RSV prophylactic drugs palivizumab and nirsevimab. The research community is hopeful that these developments might provide easier access to knowledge and might spark new ideas for research programs.

CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders

“…On the other hand, antiviral drugs are often used to treat respiratory viral illnesses like the flu or respiratory syncytial virus (RSV) [ 81 ]. Nonetheless, drug-resistant viruses can arise from mutations in viral genomes [ 82 ].…”